Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become one major obstacle for improving the clinical outcome of patients with advanced HER2 + breast cancer. While cell behaviour can be modu- --
breast cancer patients. 5, 6 Trastuzumab is designed to target HER2
and silence its function, and is mostly used for early stage or metastatic gastric and breast cancer patients with positive HER2 mutations. However, trastuzumab might be effective at initial treatments, and resistance increases substantially after a period of exposure. In addition, there is a clear need for useful therapeutic biomarkers that can be used for predicting chemo-response to trastuzumab treatment. 7 Hence, it is urgent and meaningful to reveal the mechanism of trastuzumab resistance and find useful molecular markers and therapeutic targets for breast cancer patients.
With the advanced development of whole genome and transcriptome sequencing technologies and the ENCODE project, it is more and more clear that most of the genome DNA is represented in processed transcripts without or lacking of protein-coding capacity. 8 Long non-coding RNAs (lncRNAs) are a recently discovered major class of non-coding RNAs (ncRNAs) with more than 200 nucleotides in length. 9 In recent years, emerging evidence indicates that they play important roles in regulating cellular and biological functions.
LncRNAs can regulate gene expression at post-transcriptional level via sponging microRNAs 10 and modulate transcriptional gene silencing via the chromatin regulation. 11, 12 Thus, the investigation of the role of lncRNAs in breast cancer could help with the understanding of tumorigenesis and the identification of novel diagnostic and therapeutic targets.
The lncRNAs work in a complicated way as critical regulator of epigenetic modulation, transcription and translation in a spatiotemporal manner. 13, 14 SNHG14, alternatively named UBE3A-ATS, is located on chromosome 15q11.2. SNHG14 can overlap with the entire UBE3A gene and promoter, thus inhibited the expression of UBE3A, causing neurogenetic disorders, such as Angelman syndrome. 15 Recently, Liu et al 16 demonstrated that SNHG14 could act as a ceRNA to promote initiation and progression of clear cell renal cell carcinoma by regulating N-WASP protein. Another report from
Wang et als 17 showed that SNHG14 is a tumour suppressor gene by inhibiting proliferation and invasion in glioma. These contradictory conclusions lead us to identify the function of SNHG14 in breast cancer. Currently, however, the expression pattern, biological function and underlying mechanism of SNHG14 in breast cancer progression and trastuzumab resistance are largely unknown.
In this study, we has been suggested that lncRNA SNHG14 regulated breast cancer progression and resistance via regulating PABPC1 expression through H3K27 acetylation. To verify this hypothesis, we determined the expression level of SNHG14 in breast cancer tissues and cell lines. By performing in vitro and in vivo experimental assays, we further investigated the functional relevance of SNHG14 with breast cancer progression.
| MATERIALS AND METHODS

| Patient samples
Primary cancer tissue and adjacent non-cancerous tissue samples were collected from one cohort of 36 patients with breast cancer (male/female: 0/36, range of age (median): 35- 
| Cell lines and reagents
The human breast cancer cell lines SKBR-3 and BT474, which harbour HER2 activating mutations, were purchased from Chinese Type Culture Collection, Chinese Academy of Sciences (Shanghai, China).
Both cell lines were cultured in RPMI 1640 medium (BioWhittaker, Lonza, USA) supplemented with 10 mmol/L Hepes, 1 mmol/L L-glutamine, 100 U/mL penicillin/streptomycin (BioWittaker, Lonza) and heat inactivated 10% foetal bovine serum (FBS, Gibco) at 37°C in a humidified incubator with 5% CO 2 . Trastuzumab (Herceptin) was obtained from Roche (Basel, Switzerland) and dissolved in sterile water. Trastuzumab-resistant SKBR-3/Tr and BT474/Tr cells were obtained by continuous culture with 5 mg/mL trastuzumab for 6 months as previously reported, 11, 12 and were cultured in RPMI 1640 medium with 250 μg/mL trastuzumab.
| RNA oligoribonucleotides and cell transfection
The full-length of lncRNA SNHG14 and the coding sequence of PABPC1 were amplified, cloned into the lentivirus vector for retrovirus production with BT474 cells (Lv-SNHG14 and Lv-PABPC1) by GeneChem (Shanghai, China). Negative control vectors were also generated (Lv-NC). The lentivirus vector containing shRNA sequence targeting PABPC1 (sh-PABPC1), SNHG14 (Lv-SNHG14) or negative control vector (sh-NC) was also amplified and cloned by GeneChem.
All the vectors were labelled with green fluorescence protein (GFP).
Transfection was carried out using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Transfection efficiency was evaluated in every experiment by RT-qPCR 24 hours later to ensure that cells were transfected. Functional experiments were then performed after sufficient transfection for 48 hours.
| Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
RNA was reverse transcribed using the SuperScript III ® (Invitrogen) and then the obtained cDNAs were then quantified using RT-qPCR assay labelled with SYBR (Takara Bio Company, Dalian, China) on Bio-Rad CFX96 Sequence Detection System (Bio-Rad company, Berkeley, CA, USA). The gene expression levels were normalized by GAPDH expression. RT-qPCR results were analysed and expressed relative to CT (threshold cycle) values and then converted to fold changes. All the premier sequences were synthesized by RiboBio (Guangzhou, China), and their sequences are shown as follows:
(Reverse) 5′-GAAGATGGTGATGGGA TTTC-3′.
| Cell viability assay
The altered cell viability after transfection was assayed using the 
| Cell migration and invasion assays
Cell migration was evaluated by performing wound healing assay. 
| TUNEL assay
TUNEL staining was performed to evaluate cell apoptosis. In brief, cells were fixed using 4% formaldehyde followed by staining with 
| Immunohistochemistry analysis
Immunohistochemical staining was performed on 4-μm-thick TMA slides. Briefly, the slides were deparaffinized and antigen retrieval was then performed in a steam cooker for 1.5 minutes in 1 mmol/L EDTA. Rabbit anti-PABPC1 antibody (#4992, Cell Signaling Technology, Beverly, MA, USA) at 1:150 dilution was used for culture over night at 4 □. Universal secondary antibody (DAKO) was applied for 15 minutes at room temperature. Diaminobenzidine or 3-amino-9-ethylcarbazole was used as chromogens and slides were counterstained with haematoxylin before mounting.
| In vivo tumorigenesis assay
Male BALB/C nude mice (6 weeks of age) were purchased from 
| Statistical analysis
Measurement data were shown as median value. Count dates were described as frequency and examined using Fisher's exact RT-qPCR showed that SNHG14 was up-regulated in patients who did not respond to trastuzumab treatment than those who showed response to trastuzumab therapy ( Figure 1E ). We then investigated the diagnostic potential of SNHG14 by establishing a ROC curve. As shown in Figure 1F , the area under the curve (AUC), diagnostic sensitivity and specificity for differentiating responding and nonresponding patients reached 0.776, 67.65% and 70.59% with the established cut-offs (0.033 at highest AUC), respectively. Under these stratification criteria (0.033), patients were divided into a low and a high SNHG14 expression groups, and the proportion of patients not responding to chemotherapy was significantly higher in the high SNHG14 expression group than in the low expression group ( Figure 1G ). Taken together, our clinical data indicate that SNHG14 may be a promising diagnostic marker for breast cancer patients.
| lncRNA SNHG14 promotes proliferation and invasion of breast cancer cells in vitro
We then investigated the functional role of SNHG14 in breast cancer progression and trastuzumab resistance using two HER2+ To confirm the effect of SNHG14 on cell proliferation, we detected the Ki-67 expression level by immunofluorescence assay. As expected, enhanced SNHG14 promoted Ki-67 expression, whereas SNHG14 knockdown dramatically silenced the level of Ki-67 ( Figure 2E ). Next, FACS cell cycle assay showed an increased population in G0/G1 phase and a decreased population in G2/M phase in SNHG14-overexpressed BT474 cells, whereas knockdown of SNHG14 suggested an opposite effect in SKBR-3 cells ( Figure 2F ).
Subsequently, we determined whether lncRNA SNHG14 had effects on cell migration and invasion. Wound healing assay indicated that overexpression of SNHG14 promoted cell migration, while knockdown of SNHG14 suppressed the migratory ability ( Figure 2G ). Next, transwell assay also showed that SNHG14 promoted breast cancer cell invasion ( Figure 2H ). To this end, we demonstrated that SNHG14 played an oncogenic role in breast cancer progression.
F I G U R E 1 lncRNA SNHG14 is up-regulated in breast cancer and can serve as a diagnostic indicator. A, RT-qPCR was used to detect the expression of lncRNA SNHG14 in 36 paired breast cancer tissues and adjacent non-tumour tissues. B, SNHG14 expression level was analysed in 36 primary breast cancer tissues and expressed as log 2 fold change (cancer/normal), and the log 2 fold changes were presented as follows: >1, overexpression (22 cases); <1, underexpression (4 cases); the remainder were defined as unchanged (10 cases). C, The expression level of SNHG14 was detected via RT-qPCR in breast cancer cells. D, ROC curve was drawn to show the ability of SNHG14 in differentiating breast cancer patients from healthy individuals. E, RT-qPCR was used to detect the expression of SNHG14 in 33 responding and 29 non-responding patients who received trastuzumab therapy. F, ROC curve was drawn to show the ability of SNHG14 in differentiating responding patients from non-responding patients. G, The proportion of patients that showed resistance to trastuzumab therapy was significantly higher in high SNHG14 expressing groups than in low expression group. *P < .05, **P < .01 The distribution of the cell cycle was shown in the graphs. G,H, The effects of SNHG14 on cell migration and invasion were determined using wound-heal assay and transwell invasion assay. *P < .05, **P < .01, ***P < .001 F I G U R E 3 lncRNA SNHG14 promotes trastuzumab resistance of breast cancer. A, Trastuzumab-resistant cell lines, SKBR-3/Tr and BT474/ Tr, were presented with specific morphologic changes in contrast to parental cells. Arrows show the specific changes compared to parental cells. B, The IC 50 value of trastuzumab was detected for parental and resistant cell lines by incubating at indicated concentration of trastuzumab for 48 h. C, SNHG14 expression was detected via RT-qPCR in breast cancer parental and trastuzumab-resistant cell lines. D, Cell viability was evaluated in cells treated with trastuzumab (7.0 mg/mL) for 72 h after transfection of respective oligonucleotides. E, TUNEL assay was performed after the transfected cells were treated with trastuzumab at the concentration of 7.0 mg/mL for 36. *P < .05, **P < .01 SKBR-3 parental cells. Similarly, the BT474/Tr cell was 3.29 times the ability of trastuzumab resistance of BT474 parental cells (0.79/ 0.24, Figure 3B ).
The expression level of SNHG14 in trastuzumab-resistant cells were also determined. As shown in Figure 3C , SNHG14 was up- 
| PABPC1 is a downstream target of lncRNA
SNHG14 function in breast cancer
Based on the understanding of the pathologic role of SNHG14, we continued to determine the underlying functional mechanisms. RNA-pull down experiments were performed followed by mass spectrometry to search for the SNHG14-associated proteins in breast cancer cells. As shown in Table S1 , a list of correlative SNHG14-associated proteins was identified, among which Poly(A) Binding Protein Cytoplasmic 1 (PABPC1) was chosen as a potential target of SNHG14 according to our preliminary evaluation. PABPC1 is a member of PABPC family, which binds specifically to the poly(A) tail of mRNA in cytoplasmic, is required for poly(A) shortening, ribosome recruitment and translation initiation, 19 and critical for gene regulation by interacting with other RNA-binding proteins ( Figure 4A ). Here, our in vitro experiments showed that overexpression of SNHG14 up-regulated the expression of PABPC1 at both mRNA and protein levels, whereas knockdown of SNHG14 down-regulated the expression level ( Figure 4B ).
To further investigate whether PABPC1 is a functional target of SNHG14, we constructed PABPC1-overexpression vector and PABPC1-knockdown vector ( Figure 4C ). Then, we modulated the expression of endogenous SNHG14 and PABPC1 simultaneously. 
| lncRNA SNHG14 induces an up-regulation of
PABPC1 by modulating H3K27 acetylation of the promoter region of PABPC1
To further understand the regulation of PABPC1 by SNHG14, we explored the probable mechanisms by analysis of ENCODE database (http://genome.ucsc.edu/). As shown in Figure 5A , there was high level of enrichment of H3K27ac in the promoter region of PABPC1, indicating that histone acetylation might participate in the expression of PABPC1 in transcriptional regulation. To test this hypothesis, we performed ChIP assay using SKBR-3 and BT474 cells. As shown in Figure 5B , the enrichment of H3K27ac at promoter of PABPC1 gene was identified in both cell lines. To further investigate whether lncRNA SNHG14 regulates the H3K27 acetylation at PABPC1 promoter, we sublocated the expression of SNHG14 in breast cancer cells. RT-qPCR analysis of nuclear and cytoplasmic lncRNA showed that lncRNA SNHG14 was enriched in nuclear section of both SKBR-3 and BT474 cells ( Figure 5C ). FISH assay with specific probe of SNHG14 further confirmed that SNHG14 was mainly distributed in the nuclear section of both cells ( Figure 5D ). Then, we detected the enrichment of H3K27ac in the promoter of PABPC1 by ChIP assay.
As expected, up-regulation of SNHG14 in BT474 cells increased the enrichment of H3K27ac in PABPC1, whereas knockdown of SNHG14 resulted in a decreased enrichment in SKBR-3 cells ( Figure 5E ). 
| Nrf2 pathway is promoted by the upregulation of PABPC1 induced by lncRNA SNHG14
To determine the signalling pathway that directly involved in breast cancer progression and chemo-resistance, we used Signal Reporter
Array to simultaneously investigate the activity changes of canonical signalling pathways in BT474 cells upon overexpression of SNHG14.
F I G U R E 4 PABPC1 is a downstream target of lncRNA SNHG14 function in breast cancer. A, Schematic diagram of network of PABPC1 based on ENCODE database (http://genome.ucsc.edu). B, PABPC1 was positively regulated by SNHG14 at both transcript and protein levels in breast cancer cells. C, PABPC1 expression was detected via Western blot after transfection of sh-PABPC1 or Lv-PABPC1. D, Knockdown of PABPC1 dramatically abrogated the effects of Lv-SNHG14 on cell proliferation, whereas overexpression of PABPC1 reversed the effect induced by sh-SNHG14. E, PABPC1 knockdown or overexpression vector reversed the Lv-SNHG14-or sh-SNHG14-indued effects of cell invasion, respectively. F, Cells of different groups were treated with trastuzumab (7.0 mg/mL) for 48 h, then the cell viability was determined using CCK8 assay. *P < .05, **P < .01 The five most activated and five most silenced downstream pathways are shown in Table S2 , among which we identified the Nrf2 pathway as the mostly activated one. Previous literatures suggested that Nrf2 pathway is one of the major signalling cascades involved in cell defense and survival against endogenous and exogenous stress, such as chemotherapy drugs. 20 Therefore, we has been suggested that SNHG14 may participate in breast cancer tumorigenesis via regulating Nrf2 pathway depending on PABPC1. Western blot assay was performed to test this hypothesis, and we found that 
| DISCUSSION
Extensive efforts in the past have contributed to the understanding of both molecular and cellular mechanisms of action of chemo-resistance, one of the major causes for the failure of treatment with advanced cancer types. However, little progress has been made ever since. 21 Thus, novel molecular signatures seem to hold great promise in tumour characterization and could be used as potential prognostic markers and treatment target. To identify potential molecular therapeutic markers for trastuzumab treatment, the functional relevance between lncRNA SNHG14 and breast cancer progression and trastuzumab resistance were investigated.
Our own date showed that SNHG14 promoted breast cancer tumorigenesis and chemo-resistance via activating PABPC1 through H3K27 acetylation ( Figure 7C ). 32 In addition, PABPC1 also directly participate in gastric cancer tumorigenesis by influencing cell proliferation. 33 These studies strongly suggest that PABPC1 may play an oncogenic role in cancer progression under the regulation of SNHG14. As expected, we certain genes are expressed, but also to influence how these transcripts are processed. 34 Histone acetylation is a major histone modification involved in the regulation of chromatin structure and transcription. It neutralizes the positive charge on the lysine side chain, relaxing the chromatin structure and enhancing transcriptional activity. 35 Histone acetylation named H3K27Ac was first discovered in yeast 36 and recent advancements in DNA sequencing technology have enabled the analysis of histone acetylation distribution patterns through whole genome. 37 In this study, we investigated the H3K27ac concentration at the promoter of PABPC1 by analysis of ENCODE database, followed by a serious of experimental verifications including RT-qPCR, ChIP and Western blots using breast cancer tissues and cells. We identified that PABPC1
was highly enriched with H3K27ac at the promoter of PABPC1 in breast cancer tissues. Moreover, this histone acetylation was mediated by SNHG14 as evidenced by the changed enrichment induced by overexpression or knockdown of SNHG14 in breast cancer cells.
We should address some points which need a more comprehensive investigation in future studies. First, it is still unclear whether SNHG14 directly mediates the histone acetylation or by binding with the RNA-binding proteins (RBPs), such as CREB-binding protein (CBP), which is a transcriptional co-activator with histone acetyltransferase (HAT) activity. Second, this study initially identified PABPC1 as a target protein through screening for SNHG14-interacting proteins using RNA-pulldown assay. However, we eventually verified that SNHG14 regulated the expression of PABPC1 at transcript level through mediating H3K27 acetylation. In the future, we need to reveal the underlying regulatory mechanism by which PABPC1
regulates SNHG14 expression at both transcript and protein levels.
Finally, we performed in vivo experiments to verify the in vitro results. As expected, SNHG14 abrogated the trastuzumab-induced growth suppression of xenograft tumour, indicating that SNHG14 promotes trastuzumab resistance in our mice models. Moreover, SNHG14 promotes breast cancer tumorigenesis via regulating Nfr2 pathway depending on PABPC1. In summary, our study revealed that lncRNA SNHG14 promotes breast cancer progression and chemoresistance to trastuzumab treatment both in vitro and in vivo. Therefore, SNHG14 could be considered as a promising diagnostic biomarker and therapeutic target for breast cancer patients, enhancing the clinical benefits of trastuzumab therapy.
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